Adenosine deaminase as a biomarker of tenofovir mediated inflammation in naïve HIV patients
EntityUAM. Departamento de Medicina; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (ISS-FJD)
PublisherMDPI, Basel, SMwitzerland
10.3390/ijms21103590International Journal of Molecular Sciences 21.10 (2020): 3590
Funded byThis work was supported by grants from Instituto de Salud Carlos III through the “Miguel Servet” program (CP15/00053), co-funded by Fondo Europeo de Desarrollo Regional (FEDER) and research grants from the Spanish Instituto de Salud Carlos III (PI16/00991 and PI19/00744)
ProjectGobierno de España. CP15/00053; Gobierno de España. PI16/00991; Gobierno de España. PI19/00744
SubjectsAdenosine deaminase; Biomarker; HIV; Inflammation; Tenofovir; Medicina
Rights© 2020 The Authors
Esta obra está bajo una Licencia Creative Commons Atribución 4.0 Internacional.
Plasma levels of adenosine deaminase (ADA), an enzyme that deaminates adenosine to inosine, are increased during inflammation. An increase in ADA activity occurs with lower human immunodeficiency virus (HIV) viral load and higher CD4+ T cell counts. We aimed to investigate the role of plasma ADA as a biomarker of inflammation in treatment-naïve HIV patients who received tenofovir or another nucleoside analog for comparison. Ninety-two treatment-naïve patients were included in the study and grouped by treatment, i.e., tenofovir disoproxil fumarate (TDF), tenofovir alafenamide (TAF) or Triumeq. ADA activity was measured in plasma and cytokines were analyzed by MILLIPLEX® MAP-Luminex® Technology. Plasma concentration of monocytes and neutrophils was measured at 0, 3, and 12 months post-treatment. Treatment-naïve HIV patients had increased ADA concentrations (over 15 U/L) that decreased after treatment with TAF and Triumeq, though this did not occur in TDF-treated patients. However, all groups exhibited a pro-inflammatory systemic profile at 12 months of treatment. Plasma GM-CSF levels decreased after 12 months of treatment in the TDF group, with a concomitant decrease in blood monocyte count, and a negative correlation with ADA values was found. In conclusion, ADA levels may be modulated by antiretroviral therapy in HIV patients, possibly affecting inflammatory status.
Google Scholar:Conesa-Buendía, Francisco Miguel - Llamas-Granda, Patricia - Atencio, Patricia - Cabello, Alfonso - Górgolas, Miguel - Largo, Raquel - Herrero-Beaumont, Gabriel - Mediero, Aránzazu
This item appears in the following Collection(s)
Showing items related by title, author, creator and subject.
Villalvilla, Amanda; Gómez, Rodolfo; Largo, Raquel; Herrero-Beaumont, Gabriel
Characterization of multinucleated giant cells in synovium and subchondral bone in knee osteoarthritis and rheumatoid arthritis Prieto-Potin, Iván; Largo, Raquel; Roman-Blas, Jorge A.; Herrero-Beaumont, Gabriel; Walsh, David A.
Little, Robert D.; Prieto-Potin, Iván; Pérez-Baos, Sandra; Villalvilla, Amanda; Gratal, Paula; Cicuttini, Flavia; Largo, Raquel; Herrero-Beaumont, Gabriel